Department of Chemistry, University of Kentucky, Lexington, KY 40506, USA.
Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky 40536, USA.
Free Radic Biol Med. 2019 Apr;134:1-8. doi: 10.1016/j.freeradbiomed.2018.12.029. Epub 2018 Dec 26.
Cancer treatments are developing fast and the number of cancer survivors could arise to 20 million in United State by 2025. However, a large fraction of cancer survivors demonstrate cognitive dysfunction and associated decreased quality of life both shortly, and often long-term, after chemotherapy treatment. The etiologies of chemotherapy induced cognitive impairment (CICI) are complicated, made more so by the fact that many anti-cancer drugs cannot cross the blood-brain barrier (BBB). Multiple related factors and confounders lead to difficulties in determining the underlying mechanisms. Chemotherapy induced, oxidative stress-mediated tumor necrosis factor-alpha (TNF-α) elevation was considered as one of the main candidate mechanisms underlying CICI. Doxorubicin (Dox) is a prototypical reactive oxygen species (ROS)-generating chemotherapeutic agent used to treat solid tumors and lymphomas as part of multi-drug chemotherapeutic regimens. We previously reported that peripheral Dox-administration leads to plasma protein damage and elevation of TNF-α in plasma and brain of mice. In the present study, we used TNF-α null (TNFKO) mice to investigate the role of TNF-α in Dox-induced, oxidative stress-mediated alterations in brain. We report that Dox-induced oxidative stress in brain is ameliorated and brain mitochondrial function assessed by the Seahorse-determined oxygen consumption rate (OCR) is preserved in brains of TNFKO mice. Further, we show that Dox-decreased the level of hippocampal choline-containing compounds and brain phospholipases activity are partially protected in TNFKO group in MRS study. Our results provide strong evidence that Dox-targeted mitochondrial damage and levels of brain choline-containing metabolites, as well as phospholipases changes decreased in the CNS are associated with oxidative stress mediated by TNF-α. These results are consistent with the notion that oxidative stress and elevated TNF-α in brain underlie the damage to mitochondria and other pathological changes that lead to CICI. The results are discussed with reference to our identifying a potential therapeutic target to protect against cognitive problems after chemotherapy.
癌症治疗发展迅速,到 2025 年,美国的癌症幸存者人数可能达到 2000 万。然而,大量癌症幸存者在化疗后不久,甚至常常在长期内,表现出认知功能障碍和相关的生活质量下降。化疗引起的认知障碍(CICI)的病因很复杂,由于许多抗癌药物不能穿过血脑屏障(BBB),情况更加复杂。许多相关因素和混杂因素导致确定潜在机制的困难。化疗引起的、氧化应激介导的肿瘤坏死因子-α(TNF-α)升高被认为是 CICI 潜在机制之一。多柔比星(Dox)是一种典型的活性氧(ROS)生成化疗药物,用于治疗实体瘤和淋巴瘤,作为多药化疗方案的一部分。我们之前报道过,外周给予多柔比星会导致血浆蛋白损伤和 TNF-α在血浆和小鼠大脑中的升高。在本研究中,我们使用 TNF-α 缺失(TNFKO)小鼠来研究 TNF-α在 Dox 诱导的、氧化应激介导的大脑改变中的作用。我们报告说,Dox 诱导的大脑氧化应激在 TNFKO 小鼠的大脑中得到改善,并且通过 Seahorse 测定的耗氧量(OCR)评估的大脑线粒体功能得到保留。此外,我们还表明,在 MRS 研究中,Dox 降低海马胆碱含量化合物的水平和脑磷脂酶活性在 TNFKO 组中得到部分保护。我们的研究结果提供了强有力的证据,表明 Dox 靶向的线粒体损伤以及大脑胆碱代谢物的水平,以及磷脂酶的变化,在中枢神经系统中减少与 TNF-α介导的氧化应激有关。这些结果与氧化应激和大脑中 TNF-α 升高导致线粒体和其他导致 CICI 的病理变化的观点一致。这些结果与我们确定潜在的治疗靶点以防止化疗后认知问题的观点相一致。